Literature DB >> 31952783

Mutant p53 on the Path to Metastasis.

Qiaosi Tang1, Zhenyi Su2, Wei Gu2, Anil K Rustgi3.   

Abstract

Metastasis contributes to the vast majority of cancer-related mortality. Regulatory mechanisms of the multistep invasion-metastasis cascade are being unraveled. TP53 is the most frequently mutated gene across human cancers. Accumulating evidence has shown that mutations of TP53 not only lead to loss of function or dominant negative effects, but also promotes a gain of function. Specifically, gain of function mutant p53 promotes cancer cell motility, invasion, and metastasis. Here, we summarize the mechanisms and functions of mutant p53 that foster metastasis in different types of cancers. We also discuss the prognostic value of mutant p53 and current status of therapeutic strategies targeting mutant p53. Future studies will shed light on discovering novel mechanisms of mutant p53-driven cancer metastasis and developing innovative therapeutics to improve clinical outcomes in patients harboring p53 mutations. Published by Elsevier Inc.

Entities:  

Keywords:  epithelial-to-mesenchymal transition (EMT); extracellular matrix (ECM); metastasis; mutant p53; receptor tyrosine kinase (RTK); therapeutics

Mesh:

Substances:

Year:  2019        PMID: 31952783      PMCID: PMC7485681          DOI: 10.1016/j.trecan.2019.11.004

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  114 in total

1.  PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.

Authors:  Tao Wang; Kyunghee Lee; Abdur Rehman; Sayed S Daoud
Journal:  Biochem Biophys Res Commun       Date:  2006-11-09       Impact factor: 3.575

2.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

4.  PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.

Authors:  Yayun Liang; Cynthia Besch-Williford; Salman M Hyder
Journal:  Int J Oncol       Date:  2009-11       Impact factor: 5.650

5.  Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Authors:  Fotini Vogiatzi; Dominique T Brandt; Jean Schneikert; Jeannette Fuchs; Katharina Grikscheit; Michael Wanzel; Evangelos Pavlakis; Joël P Charles; Oleg Timofeev; Andrea Nist; Marco Mernberger; Eva J Kantelhardt; Udo Siebolts; Frank Bartel; Ralf Jacob; Ariane Rath; Roland Moll; Robert Grosse; Thorsten Stiewe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

Review 6.  New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Authors:  Giovanni Blandino; Silvia Di Agostino
Journal:  J Exp Clin Cancer Res       Date:  2018-02-15

7.  Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels.

Authors:  David Novo; Nikki Heath; Louise Mitchell; Giuseppina Caligiuri; Amanda MacFarlane; Dide Reijmer; Laura Charlton; John Knight; Monika Calka; Ewan McGhee; Emmanuel Dornier; David Sumpton; Susan Mason; Arnaud Echard; Kerstin Klinkert; Judith Secklehner; Flore Kruiswijk; Karen Vousden; Iain R Macpherson; Karen Blyth; Peter Bailey; Huabing Yin; Leo M Carlin; Jennifer Morton; Sara Zanivan; Jim C Norman
Journal:  Nat Commun       Date:  2018-11-29       Impact factor: 14.919

8.  Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

Authors:  Jiajun Zhu; Morgan A Sammons; Greg Donahue; Zhixun Dou; Masoud Vedadi; Matthäus Getlik; Dalia Barsyte-Lovejoy; Rima Al-awar; Bryson W Katona; Ali Shilatifard; Jing Huang; Xianxin Hua; Cheryl H Arrowsmith; Shelley L Berger
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

9.  The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.

Authors:  P Yang; C W Du; M Kwan; S X Liang; G J Zhang
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

Review 10.  Targeting Oncogenic Mutant p53 for Cancer Therapy.

Authors:  Alejandro Parrales; Tomoo Iwakuma
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

View more
  27 in total

Review 1.  Emerging role of FBXO22 in carcinogenesis.

Authors:  Jiangting Cheng; Min Lin; Man Chu; Longyuan Gong; Yanli Bi; Yongchao Zhao
Journal:  Cell Death Discov       Date:  2020-07-27

Review 2.  Crosslink between p53 and metastasis: focus on epithelial-mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis.

Authors:  Ghader Babaei; Azadeh Aliarab; Mehdi Asghari Vostakolaei; Masumeh Hotelchi; Roghaiyeh Neisari; Shiva Gholizadeh-Ghaleh Aziz; Masumeh Rajabi Bazl
Journal:  Mol Biol Rep       Date:  2021-09-14       Impact factor: 2.316

Review 3.  p73 isoforms meet evolution of metastasis.

Authors:  Stella Logotheti; Athanasia Pavlopoulou; Stephan Marquardt; Işıl Takan; Alexandros G Georgakilas; Thorsten Stiewe
Journal:  Cancer Metastasis Rev       Date:  2022-08-11       Impact factor: 9.237

4.  Sirtuin 4 activates autophagy and inhibits tumorigenesis by upregulating the p53 signaling pathway.

Authors:  Juan Li; Hanxiang Zhan; Yidan Ren; Maoxiao Feng; Qin Wang; Qinlian Jiao; Yuli Wang; Xiaoyan Liu; Shujun Zhang; Lutao Du; Yunshan Wang; Chuanxin Wang
Journal:  Cell Death Differ       Date:  2022-10-08       Impact factor: 12.067

Review 5.  The E3 Ubiquitin Ligase Fbxo4 Functions as a Tumor Suppressor: Its Biological Importance and Therapeutic Perspectives.

Authors:  Shuo Qie
Journal:  Cancers (Basel)       Date:  2022-04-25       Impact factor: 6.575

6.  The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer.

Authors:  Pei Yu; Xiong Zhu; Jia-Le Zhu; Yu-Bao Han; Hao Zhang; Xiang Zhou; Lei Yang; Yuan-Zheng Xia; Chao Zhang; Ling-Yi Kong
Journal:  Oncogene       Date:  2021-07-09       Impact factor: 9.867

Review 7.  p53's Extended Reach: The Mutant p53 Secretome.

Authors:  Evangelos Pavlakis; Thorsten Stiewe
Journal:  Biomolecules       Date:  2020-02-15

8.  Targeting the mutant p53 secretome.

Authors:  Kartik Sehgal; David A Barbie
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 9.  Metabolic Control by DNA Tumor Virus-Encoded Proteins.

Authors:  Martin A Prusinkiewicz; Joe S Mymryk
Journal:  Pathogens       Date:  2021-05-06

10.  Identification of candidate mediators of chemoresponse in breast cancer through therapy-driven selection of somatic variants.

Authors:  Waleed S Al Amri; Diana E Baxter; Andrew M Hanby; Lucy F Stead; Eldo T Verghese; James L Thorne; Thomas A Hughes
Journal:  Breast Cancer Res Treat       Date:  2020-07-30       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.